Please use this identifier to cite or link to this item: http://repositorio.ufpa.br/jspui/handle/2011/7002
metadata.dc.type: Artigo de Periódico
Issue Date: Nov-2012
metadata.dc.creator: JUSTINO, Maria Cleonice Aguiar
ARAÚJO, Eliete da Cunha
VAN DOORN, Leen-Jan
OLIVEIRA, Consuelo Silva de
GABBAY, Yvone Benchimol
MASCARENHAS, Joana D'Arc Pereira
MIRANDA, Yllen Stefania Affonso
GUERRA, Sylvia de Fátima dos Santos
SILVA, Veronilce Borges da
LINHARES, Alexandre da Costa
Title: Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
Citation: JUSTINO, Maria Cleonice Aguiar et al. Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 107, n. 7, p. 846-853, nov. 2012. Disponível em: <http://www.scielo.br/pdf/mioc/v107n7/02.pdf>. Acesso em: 16 nov. 2015. <http://dx.doi.org/10.1590/S0074-02762012000700002>.
Abstract: In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.
Keywords: Gastroenterite
Rotavírus
Eficácia da vacina
Belém - PA
Pará - Estado
Amazônia brasileira
ISSN: 0074-0276
metadata.dc.rights: Acesso Aberto
Appears in Collections:Artigos Científicos - FAMED/ICS

Files in This Item:
File Description SizeFormat 
Artigo_OralLiveAttenuated.pdf434,94 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons